Deals
Quidel Weighs Qiagen Deal as Medical M&A QuickensÂ
- Quidel makes early approach to gauge interest in combination
- Covid test makers like Quidel face long-term growth concerns
A pharmaceutical biochemist uses a Qiagen NV automated extraction machine while processing Covid-19 tests at a laboratory in San Luis Potosi, Mexico.
Photographer: Mauricio Palos/BloombergThis article is for subscribers only.
Quidel Corp., the U.S. diagnostics firm, is weighing a combination with Qiagen NV in another sign of ongoing appetite for dealmaking in the medical equipment industry, people with knowledge of the matter said.
Quidel, which makes several types of coronavirus tests, has made a preliminary approach to Qiagen to gauge interest in a potential deal, the people said, asking not to be identified discussing confidential information.